Fortis Healthcare Ltd (FORTIS) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch
Fortis Healthcare enters Q1 FY27 results with a focus on scaling its hospital network and navigating a complex regulatory environment for oncology services. Investors will be watching for progress on the 15% revenue growth target and early signs of margin expansion following recent government drug price adjustments.
| Results date | August 06, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Previous quarter revenue | Rs. 2,365 Cr |
| Previous quarter PAT | Rs. 266 Cr |
| Previous quarter EBITDA margin | 22.5% |
| Net debt (latest quarter) | Rs. 2,334 Cr |
| Market cap | Rs. 71,343.54 Cr |
| CMP | Rs. 945.0 |
Fortis Healthcare Ltd Q1 Results Date and Time
The board meeting is scheduled for August 6, 2026, to approve the un-audited standalone and consolidated financial results for Q1 FY27.
What to expect from Fortis Healthcare Ltd's Q1 FY27 results
Fortis is targeting a 15% plus revenue growth for the hospital business in FY27, supported by seasonal disease trends that saw 3,747 dengue cases in May 2026 and a progressive increase in vector-borne illnesses. The June 12, 2026, NPPA ruling to increase ceiling prices for chemotherapy drugs by 50% provides a direct margin tailwind, potentially reversing the occupancy drag caused by the previous unviable oncology drug pricing.
While Q1 is seasonally softer than Q4, with Q1 FY26 consolidated revenue at Rs. 2,167 Cr, the company is managing a structural increase in finance costs following a year-end net debt of Rs. 2,334 Cr. Diagnostics margins are expected to stabilize toward the 23-24% range, supported by the expansion of 125+ customer touchpoints added in the previous quarter. Management's annual capex guidance of Rs. 900 Cr remains a key monitorable as the firm continues brownfield expansions at FMRI and other facilities.
Key Things To Watch
Performance vs Guidance Tracking: Monitoring progress against FY27 strategic targets.
- Hospital revenue growth target of 15%+ in FY27 — Q1 will provide the first trend data point.
- Hospital EBITDA margin improvement goal of 150 bps — Q1 margin vs Q1 FY26 (22.1%) is critical.
- Diagnostics EBITDA margin target of 23-24% — Q1 margin vs Q4 FY26 (22.0%).
- Diagnostics double-digit revenue growth — Q1 growth vs Q1 FY26 (6.3%).
- Occupancy target of above 70% — Q4 FY26 was 68%.
Strategic execution and capacity updates: Status of ongoing bed additions and management changes.
- FMRI expansion of 225 beds — first 100 beds expected to be phased by April FY27.
- Odisha O&M agreement with Dion Group — update on timeline for the 300-bed facility.
- Agilus Diagnostics — first quarterly call under new MD & CEO Mr. Vijender Singh.
Risks and headwinds to monitor: Management-flagged operational challenges.
- CGHS/ECHS oncology drug price impact — status of patient volume recovery following the June 12 NPPA price hike.
- International patient growth — monitoring if the Q4 FY26 slowdown to 11% persists.
- BG Road occupancy — targeting improvement above 60% after recent underperformance at 55%.
Ask about this
Ask Cofacto a question about this company. Answers cite filings and company data.
Frequently Asked Questions
How did the NPPA drug price hike impact Fortis Healthcare?
The NPPA raised ceiling prices for cisplatin and carboplatin by 50% on June 12, 2026, to address critical shortages. This change is a positive for Fortis, as it restores viability for oncology treatments that were previously unviable under the old price caps.
What is the current status of Fortis's bed expansion plans?
Fortis plans to add approximately 1,800 beds between FY27 and FY30. For FY27 specifically, the company is targeting 400+ brownfield beds, with major contributions expected from the FMRI facility expansion.
Is Fortis's hospital revenue growing?
Yes, management has guided for 15% plus revenue growth for the hospital business in FY27. This growth is expected to be supported by seasonal disease trends and the scaling of new units like People Tree and the Noida facilities.
Related
- Fortis Healthcare Q1 FY27 Results Analysis: Revenue Surges 17.5%, Margins Compress SharplyQ1 FY2026-2027 Results Analysis
- Fortis Healthcare Q4 FY26 Results Analysis: PAT Surges 44.6%, EBITDA Margin Expands 214 bpsQ4 FY2025-2026 Analysis
- FORTIS Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To WatchQ4 FY2025-2026 Preview